Primary immune thrombocytopenia research hub
8 indexed studies · 5 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
C1131003 - AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA
This clinical trial is looking at a new injection called PF-06835375 for adults with primary immune thrombocytopenia (ITP). ITP is a condition where the body attacks its own platelets, causing low platelet counts. The study tests whether the new medicine is safe and helps raise platelet levels.
Poland · Czechia · Hungary - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
This study looks at a medicine called efgartigimod for adults with primary immune thrombocytopenia (ITP). ITP causes low blood platelets, leading to easy bruising and bleeding. Researchers want to see if an injection under the skin is safe and helps keep platelet counts at a healthy level over time.
Italy · Romania · Greece - recruitingTherapeutic confirmatory (Phase III)
ARGX-113-1803: A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia
This study is looking at a new medicine called efgartigimod for adults with primary immune thrombocytopenia (ITP). It wants to see if the medicine is safe and how well it helps improve platelet counts over a long time. Researchers will check for side effects and how patients feel.
Italy · Czechia · Poland - active not recruitingPHASE3
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
This study looks at a new injection called efgartigimod for adults with primary immune thrombocytopenia (ITP). It aims to see how safe and effective it is. If you've been in a previous study for this treatment, you might be able to continue.
United States · Argentina · Australia - recruitingPHASE2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
This study is testing a new medicine called PF-06835375 for adults with a blood condition called Immune Thrombocytopenia (ITP). It aims to see if the medicine is safe and helps increase blood platelet counts in people who have had ITP for a few months or longer.
United States · Australia · Canada - active not recruitingPHASE3
Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia
This study compares two treatments for newly diagnosed primary immune thrombocytopenia (ITP): romiplostim plus dexamethasone versus dexamethasone alone. Researchers want to see if combining these medicines works better at keeping platelet counts up and preventing bleeding over time.
Italy · Spain · United Kingdom - active not recruitingPHASE3
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
This study is for adults with a blood condition called ITP who haven't improved with steroid treatment. It's testing a new drug called ianalumab, given with another drug called eltrombopag, to see if it can help keep blood platelet levels stable and safe for longer.
United States · Argentina · Austria - recruitingPHASE2
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
This study looks at giving a second course of ianalumab to adults with certain blood conditions (ITP or wAIHA) if their first treatment worked but then stopped or wasn't enough. It's to see if a second round is safe and helps them again.
Argentina · Belgium · China